BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hromadová D, Elewaut D, Inman RD, Strobl B, Gracey E. From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. Front Genet 2021;12:685280. [PMID: 34290741 DOI: 10.3389/fgene.2021.685280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Sen R, Caplan L. Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials. Current Opinion in Pharmacology 2022;67:102307. [DOI: 10.1016/j.coph.2022.102307] [Reference Citation Analysis]
2 Kenyon M, Maguire S, Rueda Pujol A, O'Shea F, McManus R. The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease. Rheumatol Int 2022. [PMID: 35939079 DOI: 10.1007/s00296-022-05174-5] [Reference Citation Analysis]
3 Leit S, Greenwood JR, Mondal S, Carriero S, Dahlgren M, Harriman GC, Kennedy-Smith JJ, Kapeller R, Lawson JP, Romero DL, Toms AV, Shelley M, Wester RT, Westlin W, McElwee JJ, Miao W, Edmondson SD, Masse CE. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis. Bioorg Med Chem Lett 2022;73:128891. [PMID: 35842205 DOI: 10.1016/j.bmcl.2022.128891] [Reference Citation Analysis]
4 Sun L, Wang B, Sun T, Zhou F, Zhu B, Li C, Wan H, Ding Z. Investigation on the mechanism of 2,3,4',5-Tetrahydroxystilbene 2-o-D-glucoside in the treatment of inflammation based on network pharmacology. Comput Biol Med 2022;145:105448. [PMID: 35364310 DOI: 10.1016/j.compbiomed.2022.105448] [Reference Citation Analysis]
5 Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci 2022:S0165-6147(22)00032-3. [PMID: 35277286 DOI: 10.1016/j.tips.2022.02.008] [Reference Citation Analysis]
6 Toussirot E. The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights. Pharmaceuticals 2022;15:270. [DOI: 10.3390/ph15030270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]